Morningstar

Circle Pharma Announces Poster Presentation Highlighting the Potential of CID-078, a First-in-class Oral Cyclin A/B RxL Inhibitor, at the American Association for Cancer ...

Circle Pharma Announces Poster Presentation Highlighting the Potential of CID-078, a First-in-class Oral Cyclin A/B RxL Inhibitor, at the American Association for Cancer Research Special Conference on ...
Investing

Circle Q3 2025 presentation: revenue hits $740M amid platform expansion and market share gains

Circle’s presentation highlighted the company’s growing market share in the stablecoin ecosystem. USDC’s share of total stablecoins in circulation increased from 23% in Q3 2024 to 29% in Q3 2025, ...
VentureBeat

Circle Pharma Announces Upcoming Presentation at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Circle Pharma, a biopharmaceutical company advancing the discovery and development of intrinsically cell-permeable macrocycles, today announced an upcoming poster presentation at the AACR-NCI-EORTC ...
VentureBeat

Preclinical Data on Circle Pharma’s CID-078 Featured in Poster Presentation at Advances in Neuroblastoma Research Meeting

Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced the presentation of preclinical data on CID-078 at the ...